New cocktail of chemo and precision radiation aims to tame pancreatic cancer
NCT ID NCT04570943
First seen Jan 11, 2026 · Last updated Jun 20, 2026 · Updated 25 times
Summary
This phase 2 trial tests a two-step approach for people with locally advanced pancreatic cancer that cannot be removed by surgery. First, patients receive two powerful chemotherapy regimens in sequence (GEMBRAX then FOLFIRINOX). Then, those whose cancer does not worsen get MRI-guided stereotactic radiotherapy, which delivers high-dose radiation very precisely. The goal is to stop the cancer from growing and to see if this combined treatment is safe and feasible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Carémeau
RECRUITINGNîmes, Gard, 30029, France
Contact Email: •••••@•••••
-
CHU Saint-Eloi
RECRUITINGMontpellier, Herault, 34295, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Centre Eugène Marquis
NOT_YET_RECRUITINGRennes, 35042, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Centre Georges-François Leclerc
RECRUITINGDijon, 21079, France
Contact
Contact Email: •••••@•••••
-
Hopital Paul Brousse
NOT_YET_RECRUITINGVillejuif, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hôpital Beaujon
NOT_YET_RECRUITINGClichy, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hôpital Pitié Salpétriêre
RECRUITINGParis, 75013, France
Contact Email: •••••@•••••
Contact
-
Institut Paoli Calmettes
RECRUITINGMarseille, Bouches-du-Rhône, 13009, France
Contact
Contact Email: •••••@•••••
-
Institut régional du Cancer de Montpellier
RECRUITINGMontpellier, Hérault, 34298, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gemcitabine, nab-paclitaxel, oxaliplatin, leucovorin, irinotecan, 5-fluorouracil, and MRI-guided stereotactic radiotherapy
What this could lead to
If successful, this could offer a new treatment sequence to control locally advanced pancreatic cancer and potentially make it surgically removable.
What could go wrong
This is a mid-stage trial with only 103 participants, so results may not apply broadly. Chemotherapy and radiotherapy have significant side effects, and the cancer may still progress.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.